Wu, Zhaozhen http://orcid.org/0000-0001-8962-5741
Tao, Haitao
Zhang, Sujie
Wang, Xiao
Ma, Junxun
Li, Ruixin
Liu, Zhefeng
Wang, Jinliang
Cui, Pengfei
Chen, Shixue
Di, Huang
Huang, Ziwei
Zheng, Xuan
Funding for this research was provided by:
National Basic Research Program of China (2017YFC0907904)
Article History
Received: 30 March 2020
Accepted: 5 January 2021
First Online: 19 March 2021
Compliance with ethical standards
:
: The authors declare that there is no conflict of interest.
: This retrospective study involving human participants was in accordance with the ethical standards of the national research committee and with the Helsinki Declaration. This study was approved by the ethics committee of Chinese PLA General Hospital (approval number: S2019-184-01).
: All the patients were informed of the possible treatment-related adverse events by doctors and signed informed consent before using PARP inhibitor and PD-1/PD-L1 inhibitor. Written informed consent was obtained before blood samples and tissue specimens were collected. This study does not contain any individual person’s information of patients, and all patients have consented to participate in this study and publish this paper.